证券代码：603301 证券简称：振德医疗 公告编号：2025-040 振德医疗用品股份有限公司 关于拟回购注销第一期员工持股计划部分股份 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司(以下简称:"公司")于 2025 年 7 月 23 日、8 月 11 日分别召开了第三届董事会第二十二次会议、第三届 监事会第十九次会议及 2025 年第一次临时股东大会，审议通过了《关 于回购公司第一期员工持股计划未解锁股份的议案》、《关于变更部分 回购股份用途并注销的议案》及《关于取消监事会、变更公司注册资 本、增加经营范围暨修订<公司章程>并办理工商变更登记的议案》， 拟将公司第一期员工持股计划（以下简称"本员工持股计划"）未能 解锁的 615,667 股公司股份予以回购注销。现将有关事项说明如下： 一、已履行的相关审批程序和信息披露情况 公司分别于 2021 年 5 月 24 日、2021 年 6 月 15 日召开第二届董 事会第十七次会议和 2021 年第二次临时股东大会，审议通过了《关 于< ...

Group 1 - The stock price of Zhendemedical reached a historical high, increasing by 3.02% to 88.99 yuan, with a trading volume of 4.2343 million shares and a transaction amount of 374 million yuan, resulting in a turnover rate of 1.59% [1] - The latest total market capitalization of Zhendemedical in A-shares is 23.711 billion yuan, with the same amount for the circulating market capitalization [1] - In the pharmaceutical and biotechnology industry, the overall decline is 0.86%, with 135 stocks rising and 345 stocks falling, including notable declines from Hanyu Pharmaceutical, WuXi AppTec, and Kangzhi Pharmaceutical [1] Group 2 - As of October 29, the latest margin trading balance for Zhendemedical is 1.089 billion yuan, with a financing balance of 1.088 billion yuan, reflecting an increase of 216 million yuan over the past 10 days, a growth of 24.71% [1] - The company's Q3 report indicates a total operating revenue of 3.184 billion yuan for the first three quarters, representing a year-on-year increase of 1.88%, while net profit decreased by 33.91% to 203 million yuan, with basic earnings per share at 0.7600 yuan and a weighted average return on equity of 3.57% [1]

Company Performance - Zhendemedical's stock price reached a historical high, increasing by 3.02% to 88.99 yuan, with a trading volume of 4.2343 million shares and a transaction value of 374 million yuan, resulting in a turnover rate of 1.59% [2] - The latest total market capitalization of Zhendemedical in A-shares is 23.711 billion yuan, with the circulating market capitalization also at 23.711 billion yuan [2] - The company's Q3 report indicates a total operating revenue of 3.184 billion yuan for the first three quarters, representing a year-on-year growth of 1.88%, while net profit decreased by 33.91% to 203 million yuan, with basic earnings per share at 0.7600 yuan and a weighted average return on equity of 3.57% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Zhendemedical belongs, experienced an overall decline of 0.86%, with 135 stocks rising and 3 stocks hitting the daily limit, including HeFu China and Aomei Medical [2] - Conversely, 345 stocks in the industry saw declines, with the largest drops recorded by Hanyu Pharmaceutical, WuXi AppTec, and Kangzhi Pharmaceutical, with declines of 8.97%, 7.71%, and 6.94% respectively [2] Margin Trading Data - As of October 29, the latest margin trading balance for Zhendemedical is 1.089 billion yuan, with a financing balance of 1.088 billion yuan, reflecting an increase of 216 million yuan over the past 10 days, which is a 24.71% increase [2]

Core Viewpoint - The company has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [2][3][8]. Financial Data - The financial statements for the third quarter are unaudited, covering the period from January to September 2025 [6][7]. - The report indicates that there were no profits from mergers with controlled entities during the reporting period [6]. Shareholder Information - Zhejiang ZhenDe Holdings Co., Ltd. and its wholly-owned subsidiary, Xuchang ZhenDe Landscaping Engineering Co., Ltd., have signed a share transfer agreement to transfer a total of 13,322,560 shares, representing 5.00% of the company's total share capital, at a price of RMB 26.74 per share [5]. - The total transfer amount is RMB 356,245,254.40 [5]. Investor Communication - The company will hold an investor briefing on November 13, 2025, from 10:00 to 11:00 AM, to discuss the third-quarter results and address investor questions [9][10]. - Investors can submit questions from November 6 to November 12, 2025, through the Shanghai Stock Exchange Roadshow Center [12].

Group 1 - The core viewpoint of the article highlights the financial performance of Zhendé Medical for the third quarter of 2025, indicating a slight increase in revenue but a significant decrease in net profit and earnings per share [1] Group 2 - Zhendé Medical reported revenue of approximately 3.184 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.88% [1] - The net profit attributable to shareholders of the listed company was approximately 203 million yuan, showing a year-on-year decrease of 33.91% [1] - The basic earnings per share were 0.76 yuan, which also reflects a year-on-year decrease of 33.91% [1] - As of the report date, Zhendé Medical's market capitalization stood at 23 billion yuan [2]

Core Insights - The company reported a slight increase in revenue for Q3 2025, with a total of 1.084 billion yuan, representing a year-on-year growth of 0.10% [1] - However, the net profit attributable to shareholders saw a significant decline of 48.47%, amounting to 75.422 million yuan [1] - For the first three quarters of 2025, the company achieved a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%, while the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [1] Revenue Analysis - Q3 2025 revenue reached 1.084 billion yuan, showing a marginal increase compared to the previous year [1] - Year-to-date revenue for the first three quarters totaled 3.184 billion yuan, indicating a modest growth of 1.88% [1] Profitability Overview - The net profit for Q3 2025 was 75.422 million yuan, down 48.47% year-on-year [1] - The net profit for the first three quarters was 203 million yuan, which is a decline of 33.91% compared to the same period last year [1] Key Factors Impacting Performance - The decline in net profit is primarily attributed to the previous year's asset disposal gains from the acquisition of state-owned land use rights and properties, which contributed approximately 93 million yuan to the net profit in the same period last year [1]

证券代码：603301 证券简称：振德医疗 公告编号：2025-039 振德医疗用品股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2025 年 11 月 13 日（星期四）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星 期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告。为便于广大投资者更全 面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划 于 2025 年 11 月 1 ...

振德医疗用品股份有限公司 2025 年第三季度报告 证券代码：603301 证券简称：振德医疗 振德医疗用品股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 1,084,062,685.61 | 0.10 | 3,184,260,011.92 | 1. ...

Core Viewpoint - On October 28, 2025, Zhendemedical (603301) closed at 80.95 yuan, reaching the daily limit with a 10.0% increase, indicating strong market interest and trading activity [1][2]. Trading Information Summary - The stock hit the daily limit at 9:45 AM, with a total of 8 instances of the limit being opened during the trading day, and the final closing order amount was 49.1451 million yuan, accounting for 0.23% of its circulating market value [1][2]. - On the same day, the net inflow of main funds was 62.9061 million yuan, representing 4.91% of the total transaction amount, while speculative funds experienced a net outflow of 106 million yuan, which was 8.28% of the total transaction amount [1][2]. - Retail investors saw a net inflow of 43.1042 million yuan, making up 3.37% of the total transaction amount [1][2].

Market Overview - On October 28, the medical device sector rose by 0.21%, led by Chutian Technology, while the Shanghai Composite Index closed at 3988.22, down 0.22%, and the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Top Performers - Chutian Technology (300358) closed at 11.32, with a significant increase of 20.04% and a trading volume of 842,800 shares, amounting to a transaction value of 924 million yuan [1]. - Libang Instruments (300206) saw a closing price of 13.97, up 15.45%, with a trading volume of 521,600 shares and a transaction value of 718 million yuan [1]. - Zhend Medical (603301) closed at 80.95, increasing by 10.00%, with a trading volume of 159,900 shares [1]. Underperformers - Sino Medical (688108) experienced a decline of 9.39%, closing at 25.19, with a trading volume of 415,300 shares and a transaction value of 1.084 billion yuan [2]. - Yingke Medical (300677) closed at 38.56, down 8.58%, with a trading volume of 333,700 shares [2]. - Nanwei Medical (688029) saw a decrease of 6.30%, closing at 81.52, with a trading volume of 56,100 shares [2]. Capital Flow - The medical device sector experienced a net outflow of 405 million yuan from institutional investors, while retail investors saw a net inflow of 417 million yuan [2][3]. - Chutian Technology had a net inflow of 162.16 million yuan from institutional investors, while retail investors had a net outflow of 64.44 million yuan [3]. - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are actively buying [2][3].